{"type":"profile","id":"profile=medica2026.3084047","exhSeoId":"fBMNgpYYRoyHzYaPo56TFQ","name":"Genera Research Ltd.","email":"dora.adanic@genera-research.com","getInTouchEmail":"dora.adanic@genera-research.com","logo":"https://www.medica.de/vis-content/event-medica2026/exh-medica2026.3084047/MEDICA-2026-Genera-Research-Ltd.-Exhibitor-base-data-medica2026.3084047-NImzkloGQWqYqxiGWbZwzA-image.jpg","profileAddress":{"address":["Ulica Braće Radić 2"],"city":"Sveta Nedelja","zip":"10436","country":"Croatia","countryCode":"HR"},"phone":{"phone":"+385 1 2229664"},"links":[{"id":"link=rXwiqgFFQTaLjigIokrwaA","type":"link","link":"https://genera-research.com","parentType":"profile","order":1,"visibleInLang":["en","de"]}],"media":[{"id":"video=2c6QD6ffQxWju90aTXywWg","type":"video","title":"OSTEOGROW","text":"Promotional video for OSTEOGROW, about 3 minutes long, with spoken narration and burned-in English subtitles. It opens with the colourful OSTEOGROW logo on a white background. Prof. Slobodan Vukičević, Chief Medical Officer, stands in front of a light blue backdrop with the OSTEOGROW logo and introduces Genera Research and its work on bone defects and spinal diseases. Simple hand-drawn animations in burgundy and pink follow: a syringe combining a blood sample, BMP6 and biomechanical material; a cheerful cartoon bone character; a spine with a calendar showing how long healing takes; and an arm with a highlighted forearm bone being treated. Prof. Vukičević and Mihaela Perić, Ph.D., Chief Regulatory Consultant, then explain the clinical results, the proven safety and the plan for Phase III pivotal trials. Short lab clips show scientists in protective clothing working at a microscope, in a cleanroom and with lab equipment. Dora Adanić, Chief Financial Officer, in a red blazer, talks about clinical trial costs, market potential, EU funding and scaling up production. The video ends with both presenters together on the team's growth and the goal of better therapies, then fades back to the OSTEOGROW logo.","parentType":"profile","videoId":"1230902396","videoBlindSuitable":true,"videoDeafSuitable":true,"videoUploaded":true,"videoHasTexttrack":false,"order":1,"visibleInLang":["en","de"]}],"locations":[{"areaId":"15","area":"Hall 15","stand":"C47"}],"location":"Hall 15 / C47","locationIsVirtual":false,"events":[{"key":"medica2026","label":"MEDICA 2026"}],"eventIcons":[{"label":"MEDICA 2026","src":"https://www.medica.de/vis-content/event-medica2026/all-exh/Event-0mOSbpheSRej6t2ZLcI1AA.png"}],"eventMap":"https://iahapla02.messe-duesseldorf.de/en/2dexgroundV2/medica2026/3084047.svg","areaMap":"https://iahapla02.messe-duesseldorf.de/en/3dhallV2/medica2026/15/3084047.svg","areaId":"15","mainExhibitor":{"id":"medica2026.3080440","label":"European Innovation Council","exhSeoId":"SBqXcBvyQeKAHgG96O8b4Q"},"premium":false,"exhIsLead":false,"logoUploadedByPubimport":true,"tags":[{"id":"tag=medica2026.0","label":"Manufacturer","icon":"md md-tag-label md-tag-label-m"}],"xtags":[],"socialMedia":[{"title":"LinkedIn","link":"https://www.linkedin.com/company/genres","network":"linkedin","standardDomain":"https://www.linkedin.com/"}],"synonyms":[],"text":"

Genera Research – Regrowing bone with the patient's own blood

OSTEOGROW platform

OSTEOGROW turns a patient's own blood into new bone. A small dose of recombinant human bone morphogenetic protein 6 (rhBMP6) is mixed with the patient's blood in the operating room, forming a natural clot that releases the bone-forming signal exactly where it is needed. No animal-derived collagen, no donor tissue, and no second surgery to harvest the patient's own bone. Completed clinical trials have treated more than 250 patients. In those trials, no treatment-related serious adverse events occurred, and no patient developed antibodies against rhBMP6. One platform is being developed for three indications: nonunion fractures, spinal fusion, and dental bone regeneration.


Genera Research is a Croatian clinical-stage biopharmaceutical company, founded in 2001 near Zagreb. We are developing OSTEOGROW, a new treatment for bone regeneration. It combines our recombinant human bone morphogenetic protein 6 (rhBMP6, INN bezeotermin alfa) with an autologous blood coagulum made from the patient's own blood. Because it uses no animal-derived or synthetic carriers, OSTEOGROW works with the body's natural healing process to form new bone where it has failed to form on its own.


What makes us special


Our goals

We are moving OSTEOGROW into Phase III for fracture non-union (OSTEOforUNION), alongside programs in spinal fusion and dental bone augmentation. We want to give patients and surgeons an effective biological alternative to bone grafting and repeat surgery.


Our challenge

We are raising a Series A round and looking for a lead investor to match the €5.8M EIC equity commitment. The EIC's 1:1 matching gives new investors strong capital efficiency. We are also open to strategic partners in orthopedics, spine, and dental, as well as licensing and distribution partners in key markets.


Our vision

We want to make OSTEOGROW the standard of care for difficult bone healing worldwide: a safer, simpler and more natural way to restore mobility and quality of life.


Meet us at the EIC Pavilion, MEDICA 2026, Düsseldorf, 16–19 November.



","pdfs":[{"id":"paper=dzaMYC0eRomUHAdPDLbejg","type":"paper","title":"GENERA-letak-qr kod","source":"https://www.medica.de/vis-content/event-medica2026/exh-medica2026.3084047/MEDICA-2026-Genera-Research-Ltd.-Paper-medica2026.3084047-l0TIGMQcQRif9zBcZdilRA.pdf","parentType":"profile","fileName":"GENERA-letak-qr kod.pdf","order":1,"visibleInLang":["en","de"]}],"tol":[],"categories":[{"id":"prod=medica2026.01.06.01","label":"Implants & prosthetics","catalogIndex":"01.06.01","eventIcons":[{"key":"medica2026","small":"https://www.medica.de/vis-content/event-medica2026/all-exh/Event-SzHinHZFRDix2fwVNyP4ag.png","tiny":"https://www.medica.de/vis-content/event-medica2026/all-exh/Event-0mOSbpheSRej6t2ZLcI1AA.png","label":"MEDICA 2026"}],"productList":[{"id":"prodinfo=i85NCBQUQ8W4fXzn5hfCaA","label":"OSTEOforUNION: OSTEOGROW-C for fractures that will not heal"},{"id":"prodinfo=CQR11quiTVKaqx758UGa5w","label":"OSTEOproSPINE: spinal fusion for degenerative disc disease"},{"id":"prodinfo=VPi06XLxTFus5CA2Rb0oOw","label":"OSTEOproDENT: rebuilding jawbone for dental implants"}],"hierarchy":[{"id":"01","label":"Clinical Diagnostics & Therapeutic Technologies"},{"id":"01.06","label":"Orthopaedics, Trauma & Rehabilitation"},{"id":"01.06.01","label":"Implants & prosthetics"}]},{"id":"prod=medica2026.01.06.02","label":"Trauma systems","catalogIndex":"01.06.02","eventIcons":[{"key":"medica2026","small":"https://www.medica.de/vis-content/event-medica2026/all-exh/Event-SzHinHZFRDix2fwVNyP4ag.png","tiny":"https://www.medica.de/vis-content/event-medica2026/all-exh/Event-0mOSbpheSRej6t2ZLcI1AA.png","label":"MEDICA 2026"}],"productList":[{"id":"prodinfo=i85NCBQUQ8W4fXzn5hfCaA","label":"OSTEOforUNION: OSTEOGROW-C for fractures that will not heal"},{"id":"prodinfo=CQR11quiTVKaqx758UGa5w","label":"OSTEOproSPINE: spinal fusion for degenerative disc disease"},{"id":"prodinfo=VPi06XLxTFus5CA2Rb0oOw","label":"OSTEOproDENT: rebuilding jawbone for dental implants"}],"hierarchy":[{"id":"01","label":"Clinical Diagnostics & Therapeutic Technologies"},{"id":"01.06","label":"Orthopaedics, Trauma & Rehabilitation"},{"id":"01.06.02","label":"Trauma systems"}]},{"id":"prod=medica2026.01.06.04","label":"Exoskeletons","catalogIndex":"01.06.04","eventIcons":[{"key":"medica2026","small":"https://www.medica.de/vis-content/event-medica2026/all-exh/Event-SzHinHZFRDix2fwVNyP4ag.png","tiny":"https://www.medica.de/vis-content/event-medica2026/all-exh/Event-0mOSbpheSRej6t2ZLcI1AA.png","label":"MEDICA 2026"}],"productList":[],"hierarchy":[{"id":"01","label":"Clinical Diagnostics & Therapeutic Technologies"},{"id":"01.06","label":"Orthopaedics, Trauma & Rehabilitation"},{"id":"01.06.04","label":"Exoskeletons"}]}],"write":false,"lastModified":"2026-11-04T10:18:09Z","tagsAreEditable":false,"xtagsAreEditable":false,"isGetInTouchAllowed":false}